LC
CRBU icon

Lindbrook Capital’s Caribou Biosciences CRBU Stock Holding History

Lindbrook Capital’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-703
Closed -$3.61K – 2770
2024
Q1 		$3.61K Hold
703
– – ﹤0.01% 2038
2023
Q4 		$4.03K Buy
703
+434
+161% +$2.15K ﹤0.01% 2006
2023
Q3 		$1.29K Buy
+269
New +$1.67K ﹤0.01% 2277
2023
Q1 		– Sell
-57
Closed -$358 – 2805
2022
Q4 		$358 Buy
+57
New +$507 ﹤0.01% 2647

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lindbrook Capital's CRBU Position: Q2 2024 in Review

Lindbrook Capital sold out of Caribou Biosciences (CRBU) in Q2 2024, closing a stake of 703 shares — an estimated $3.61K sold.

Lindbrook Capital first reported a position in CRBU in Q4 2022 and held it in 4 quarters. The position peaked at $4.03K in Q4 2023. 140 funds tracked by Wall St. Rank hold CRBU as of Q2 2024.

  • Lindbrook Capital reported no remaining Caribou Biosciences position as of Q2 2024 after selling out during the quarter.
  • Lindbrook Capital sold 703 Caribou Biosciences shares in Q2 2024, an estimated $3.61K.
  • Lindbrook Capital first reported a position in Caribou Biosciences in Q4 2022 and held it in 4 quarters.
  • Lindbrook Capital's Caribou Biosciences position peaked at $4.03K in Q4 2023.
  • 140 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2024.

Based on Lindbrook Capital's 13F filing for Q2 2024, filed 31 Jul 2024.